ORIC Pharmaceuticals, Inc.
ORIC
Price:
$9.99
Market Cap:
$704.72M
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company i...[Read more]
Industry
Biotechnology
IPO Date
2020-04-24
Stock Exchange
NASDAQ
Ticker
ORIC
The ROE as of September 2024 (TTM) for ORIC Pharmaceuticals, Inc. (ORIC) is -40.19%
According to ORIC Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -40.19%. This represents a change of 290.96% compared to the average of -10.28% of the last 4 quarters.
ORIC Pharmaceuticals, Inc. (ORIC) Historical ROE (quarterly & annually)
How has ORIC ROE performed in the past?
The mean historical ROE of ORIC Pharmaceuticals, Inc. over the last ten years is -32.79%. The current -40.19% ROE has changed 22.57% with respect to the historical average. Over the past ten years (40 quarters), ORIC's ROE was at its highest in in the March 2020 quarter at 9.01%. The ROE was at its lowest in in the March 2019 quarter at -14.04%.
Average
-32.79%
Median
-33.57%
Minimum
-85.63%
Maximum
33.16%
ORIC Pharmaceuticals, Inc. (ORIC) ROE by Quarter and Year
Discovering the peaks and valleys of ORIC Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 44.58%
Maximum Annual ROE = 33.16%
Minimum Annual Increase = -187.37%
Minimum Annual ROE = -85.63%
| Year | ROE | Change |
|---|---|---|
| 2023 | -44.94% | 9.23% |
| 2022 | -41.14% | 44.58% |
| 2021 | -28.46% | -15.23% |
| 2020 | -33.57% | 15.87% |
| 2019 | -28.97% | -187.37% |
| 2018 | 33.16% | -138.72% |
ORIC Pharmaceuticals, Inc. (ORIC) Average ROE
How has ORIC ROE performed in the past?
The current ROE of ORIC Pharmaceuticals, Inc. (ORIC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-38.18%
5-year avg
-35.41%
10-year avg
-32.79%
ORIC Pharmaceuticals, Inc. (ORIC) ROE vs. Peers
How is ORIC’s ROE compared to its peers?
ORIC Pharmaceuticals, Inc.’s ROE is greater than Seer, Inc. (-21.26%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Cullinan Oncology, Inc. (-28.37%), greater than C4 Therapeutics, Inc. (-44.60%), less than Molecular Partners AG (0%), greater than Mineralys Therapeutics, Inc. (-33.08%), greater than AN2 Therapeutics, Inc. (-42.61%), greater than Pharvaris N.V. (-54.72%), greater than PepGen Inc. (-36.89%), greater than Werewolf Therapeutics, Inc. (-62.74%), greater than Edgewise Therapeutics, Inc. (-48.25%), greater than Decibel Therapeutics, Inc. (-28.01%), greater than Celcuity Inc. (-84.03%), greater than Theseus Pharmaceuticals, Inc. (-60.83%), greater than PMV Pharmaceuticals, Inc. (-24.51%), greater than Enliven Therapeutics, Inc. (-21.96%), greater than Immuneering Corporation (-29.31%), greater than null (-66.03%),
| Company | ROE | Market cap |
|---|---|---|
| -21.26% | $103.20M | |
| -122.97% | $54.20M | |
| -28.37% | $981.54M | |
| -44.60% | $440.99M | |
| 0% | $172.94M | |
| -33.08% | $576.83M | |
| -42.61% | $31.33M | |
| -54.72% | $1.11B | |
| -36.89% | $297.22M | |
| -62.74% | $93.52M | |
| -48.25% | $1.58B | |
| -28.01% | $123.37M | |
| -84.03% | $560.64M | |
| -60.83% | $181.50M | |
| -24.51% | $77.28M | |
| -21.96% | $1.06B | |
| -29.31% | $85.11M | |
| -66.03% | $0 |
Build a custom stock screener for ORIC Pharmaceuticals, Inc. (ORIC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ORIC Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ORIC Pharmaceuticals, Inc. (ORIC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ORIC Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ORIC Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for ORIC Pharmaceuticals, Inc. (ORIC)?
What is the highest ROE for ORIC Pharmaceuticals, Inc. (ORIC)?
What is the 3-year average ROE for ORIC Pharmaceuticals, Inc. (ORIC)?
What is the 5-year average ROE for ORIC Pharmaceuticals, Inc. (ORIC)?
How does the current ROE for ORIC Pharmaceuticals, Inc. (ORIC) compare to its historical average?